Miltefosine and cutaneous leishmaniasis

Current Opinion in Infectious Diseases, 03/02/2012

The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large–scale use in the inner regions of the endemic countries. Miltefosine also shows activity in severe or refractory cases. However, this review points out the need for further investment on clinical research into cutaneous leishmaniasis treatment.

Print Article Summary Cat 2 CME Report